2024
Association of mental health related quality of life and other factors with treatment seeking for substance use disorders: A comparison of SUDs rooted in legal, partially legal, and illegal substances
Havlik J, Rhee T, Rosenheck R. Association of mental health related quality of life and other factors with treatment seeking for substance use disorders: A comparison of SUDs rooted in legal, partially legal, and illegal substances. PLOS ONE 2024, 19: e0302544. PMID: 38683850, PMCID: PMC11057773, DOI: 10.1371/journal.pone.0302544.Peer-Reviewed Original ResearchConceptsIllicit substance use disordersCannabis use disorderSubstance use disordersMental health-related quality of lifeUse disorderTreatment usePast-year CUDRates of treatment usePast-year substance use disorderMental health-related qualityMental health related qualityBehavioral health factorsLegal statusNegative associationNESARC-IIISUD treatment useMultiple regression analysisDisordersHealth-related quality of lifeIllegal substancesHealth related qualityUnadjusted analysisQuality of lifeAUDDiagnostic factors
2023
Association of Recent and Past Suicide Attempts With Health-Related Quality of Life.
Bommersbach T, Rosenheck R, Rhee T. Association of Recent and Past Suicide Attempts With Health-Related Quality of Life. The Journal Of Clinical Psychiatry 2023, 84 PMID: 36856537, DOI: 10.4088/jcp.22m14441.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcohol-Related DisordersCost-Benefit AnalysisHumansMental HealthQuality of LifeSuicide, AttemptedConceptsMental component scorePhysical component scoreSuicide prevention initiativesSuicide attemptsOverall health-related qualityMajor public health priorityPrevention initiativesHealth-related qualitySubstance use comorbiditiesMeasures of HRQOLRelated Conditions Wave IIILower MCS scoresMultivariable regression analysisPublic health prioritySubstance use disordersComponent scoresNational Epidemiologic SurveyQuality of lifeRecent suicide attemptAssociation of suicidePast suicide attemptsPrior attemptsMCS scoresUnadjusted analysesHealth priorityMultimorbidity and Correlates of Comorbid Depression and Generalized Anxiety Disorder in a Nationally Representative US Sample
Jegede O, Stefanovics E, Rhee T, Rosenheck R. Multimorbidity and Correlates of Comorbid Depression and Generalized Anxiety Disorder in a Nationally Representative US Sample. The Journal Of Nervous And Mental Disease 2023, 211: 355-361. PMID: 36807207, DOI: 10.1097/nmd.0000000000001625.Peer-Reviewed Original ResearchMeSH KeywordsAnxiety DisordersChildComorbidityDepressionDepressive Disorder, MajorHumansMultimorbidityQuality of LifeConceptsMajor depressive disorderAdditional psychiatric diagnosesRepresentative US sampleComorbid groupPsychiatric disordersPsychiatric diagnosisPoor mental health qualityMental health-related qualityPoorer mental health-related qualityAnxiety disordersHealth-related qualityAdditional psychiatric disordersNationally Representative US SampleMental health qualityLogistic regression analysisSubstance use disordersNational Epidemiologic SurveyMDD-only groupRelated Conditions-IIISingle disorder groupsGeneralized anxiety disorderSingle diagnosis groupsPsychiatric comorbidityComorbid depressionDepressive disorderGender differences in outcomes of early intervention services for first episode psychosis
Hong S, Bennett D, Rosenheck R. Gender differences in outcomes of early intervention services for first episode psychosis. Early Intervention In Psychiatry 2023, 17: 715-723. PMID: 36623822, PMCID: PMC10329725, DOI: 10.1111/eip.13367.Peer-Reviewed Original ResearchMeSH KeywordsAntipsychotic AgentsFemaleHumansMalePsychotic DisordersQuality of LifeSchizophreniaSex FactorsConceptsFirst-episode psychosisEarly intervention servicesClinical trialsEpisode psychosisInitial Schizophrenia Episode-Early Treatment Program (RAISE-ETP) studyEarly interventionIntervention servicesRandomized clinical trialsComorbid substance useUS clinical trialsSignificant gender differencesNegative Syndrome ScaleBaseline gender differencesGender differencesSchizophrenia spectrum disordersAntipsychotic exposureUsual careBaseline characteristicsMood symptomsDepression subscalePsychotic disordersMasked evaluatorsSchizoaffective disorderSyndrome ScaleSecondary analysis
2022
Beyond Supported Housing: Correlates of Improvements in Quality of Life Among Homeless Adults with Mental Illness
O’Connell M, Tsai J, Rosenheck R. Beyond Supported Housing: Correlates of Improvements in Quality of Life Among Homeless Adults with Mental Illness. Psychiatric Quarterly 2022, 94: 49-59. PMID: 36538200, DOI: 10.1007/s11126-022-10010-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultHousingHumansIll-Housed PersonsMental DisordersQuality of LifeSubstance-Related Disorders
2007
Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics
Rosenheck R. Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics. The British Journal Of Psychiatry 2007, 191: 238-245. PMID: 17766765, DOI: 10.1192/bjp.bp.106.035063.Peer-Reviewed Original Research
2006
Special Section on CATIE Baseline Data: Components and Correlates of Family Burden in Schizophrenia
Perlick D, Rosenheck R, Kaczynski R, Swartz M, Cañive J, Lieberman J. Special Section on CATIE Baseline Data: Components and Correlates of Family Burden in Schizophrenia. Psychiatric Services 2006, 57: 1117-1125. PMID: 16870962, DOI: 10.1176/ps.2006.57.8.1117.Peer-Reviewed Original ResearchConceptsMedication side effectsQuality of lifeDaily livingService useSide effectsAcute inpatient phaseImpact of symptomsPatient problem behaviorsClinical Antipsychotic TrialsPatient's symptomsCaregiver burdenInpatient phaseAntipsychotic TrialsFamily burdenFamily caregiversCaregiver dataPatient behaviorTreatment programPatients' impairmentIncorporation of skillsSymptomsIntervention effectivenessDemographic characteristicsPrevious monthSchizophrenia
2001
Time-Limited Assertive Community Treatment for Homeless Persons With Severe Mental Illness
Rosenheck RA, Dennis D. Time-Limited Assertive Community Treatment for Homeless Persons With Severe Mental Illness. JAMA Psychiatry 2001, 58: 1073-1080. PMID: 11695955, DOI: 10.1001/archpsyc.58.11.1073.Peer-Reviewed Original ResearchConceptsSevere mental illnessMental illnessService useHealth statusOutpatient health service useSubstance abuseAssertive community treatment modelHealth service useAssertive community treatmentMental health statusRandom-effects modelCommunity treatment modelHospital daysPublic support paymentsCommunity treatmentCommunity careIllnessMental healthMore daysMonthsTreatment modelHomeless personsEffects modelAnnual cohortsHomeless clientsDetecting Improvement in Quality of Life and Symptomatology in Schizophrenia
Cramer J, Rosenheck R, Xu W, Henderson W, Thomas J, Charney D, Schizophrenia D. Detecting Improvement in Quality of Life and Symptomatology in Schizophrenia. Schizophrenia Bulletin 2001, 27: 227-234. PMID: 11354590, DOI: 10.1093/oxfordjournals.schbul.a006869.Peer-Reviewed Original Research
2000
Quality of Life in Schizophrenia: A Comparison of Instruments
Cramer J, Rosenheck R, Xu W, Thomas J, Henderson W, Schizophrenia D. Quality of Life in Schizophrenia: A Comparison of Instruments. Schizophrenia Bulletin 2000, 26: 659-666. PMID: 10993404, DOI: 10.1093/oxfordjournals.schbul.a033484.Peer-Reviewed Original ResearchConceptsHealth-related qualityClinical trialsTreatment effectsPatient-reported qualityLife InterviewGlobal clinical ratingsLife ScaleQuality of lifePatient responseModerate-high correlationClinical ratingsFunction scaleSymptom severitySchizophreniaStructured interviewsTrialsComparison of instrumentsRaters' assessmentsClozapineHaloperidolInpatientsLifeMultiple measuresSeverity
1999
Interrater Reliability Levels of Multiple Clinical Examiners in the Evaluation of a Schizophrenic Patient: Quality of Life, Level of Functioning, and Neuropsychological Symptomatology
Cicchetti D, Rosenheck R, Showalter D, Charney D, Cramer J. Interrater Reliability Levels of Multiple Clinical Examiners in the Evaluation of a Schizophrenic Patient: Quality of Life, Level of Functioning, and Neuropsychological Symptomatology. The Clinical Neuropsychologist 1999, 13: 157-170. PMID: 10949157, DOI: 10.1076/clin.13.2.157.1965.Peer-Reviewed Original Research
1998
Predictors of differential response to clozapine and haloperidol
Rosenheck R, Lawson W, Crayton J, Cramer J, Xu W, Thomas J, Stolar M, Charney D, Schizophrenia F. Predictors of differential response to clozapine and haloperidol. Biological Psychiatry 1998, 44: 475-482. PMID: 9777179, DOI: 10.1016/s0006-3223(98)00117-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAntipsychotic AgentsClozapineDouble-Blind MethodDrug ResistanceFemaleHaloperidolHumansMalePsychiatric Status Rating ScalesQuality of LifeRacial GroupsSchizophreniaSchizophrenic PsychologySocial SupportTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsConceptsQuality of lifeThree-month outcomeOnset of schizophreniaSeverity of symptomsGreater symptom reductionGreater improvementRefractory patientsRefractory schizophreniaClozapine treatmentHospital daysClinical predictorsExtrapyramidal symptomsHospitalized patientsClinical trialsBaseline predictorsSample patientsSide effectsSymptom reductionClozapinePatientsSymptomsHigher symptomsHigh levelsHaloperidolMultiple regression analysis
1997
A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia
Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D. A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia. New England Journal Of Medicine 1997, 337: 809-815. PMID: 9295240, DOI: 10.1056/nejm199709183371202.Peer-Reviewed Original ResearchConceptsClozapine groupExtrapyramidal side effectsHaloperidol groupRefractory schizophreniaSide effectsAntipsychotic drugsDouble-blind comparative studyVeterans Affairs Medical CenterMore outpatient servicesNegative Syndrome ScaleComparison of clozapineLower symptom levelsSimilar overall costsHospitalized patientsTreat analysisTardive dyskinesiaPsychiatric reasonsLower incidenceMedical CenterOutpatient servicesHospital usePatientsSyndrome ScaleClozapineHaloperidol